Prenetics Global Limited shares were in focus after the company announced a multi-year global partnership for its IM8 consumer health brand, naming actress and producer Lily Collins as an IM8 Global Ambassador and as a shareholder in Prenetics. The move signals a push to broaden IM8’s audience beyond its existing sports and wellness collaborations, with Collins slated to participate in global marketing, brand content, and product initiatives.
Key takeaways
- Price move: The announcement comes while Prenetics Global Limited has traded between $7.18 and $23.63 over the past year, with the stock last quoted at $18.76.
- Catalyst: The company secured Lily Collins as IM8’s first film-and-television ambassador and added her to an equity-aligned group of global partners.
- Key implication: Prenetics is using entertainment-facing influence to deepen IM8’s reach—particularly among female consumers—alongside its international expansion and new product pipeline.
- Growth backdrop: IM8 scale and improved cash flow supported a revised outlook, including higher fiscal 2026 revenue guidance.
What drove the move
Prenetics said Collins will serve as IM8 Global Ambassador and take a shareholder position in the company. Collins is expected to appear in IM8’s global marketing campaigns and contribute to brand content and product initiatives.
According to the company, Collins brings more than 33 million followers across social platforms, and her addition is intended to strengthen IM8’s connection with female consumers. Prenetics described the partnership as its first ambassador from film and television, expanding IM8’s ambassador roster beyond existing sports and wellness-focused collaborations.
How IM8 is scaling
Prenetics’ announcement also reiterated the operational and product fundamentals behind IM8’s growth strategy.
IM8 Daily Ultimate Essentials, the brand’s flagship offering, is positioned as a single daily sachet containing 90 science-backed ingredients designed to replace 16 supplements in one drink. Since IM8’s December 2024 launch, Prenetics said the product has delivered more than 57 million servings.
The company reported current shipping activity of approximately 200,000 servings per day, with an order placed every 27 seconds. IM8 is now sold in 46 countries, and Prenetics said 54% of revenue is generated outside the U.S.
Management also outlined further expansion. IM8 Hydration is scheduled to launch in the fourth quarter of 2026, and a premium gummies line is planned for the first half of 2027. The product additions are meant to extend IM8’s portfolio and maintain momentum as distribution widens.
Financial outlook and cash-flow progress
Alongside the ambassador news, Prenetics highlighted an upgraded financial trajectory driven by IM8 growth and cash-flow improvement.
According to the company, Prenetics raised its fiscal year 2026 revenue guidance to $220 million to $230 million, following a reported 480% increase in total revenue to $92.4 million in fiscal year 2025. Prenetics also initiated fiscal year 2027 revenue guidance of $400 million or more.
On cash flow, Prenetics said it achieved positive consolidated Adjusted Free Cash Flow in July 2026. The company expects to remain consolidated Adjusted Free Cash Flow positive for the full third quarter of 2026 and beyond. For investors, that matters because improving cash generation can reduce reliance on external financing as marketing efforts and inventory build-out scale internationally.
Market reaction: what investors are likely watching
While the partnership itself is a marketing catalyst, the market focus is likely to be on whether increased brand visibility translates into sustained demand across geographies and categories. The ambassador announcement pairs with operational scale—daily shipment volumes and distribution across 46 countries—creating a narrative of brand expansion rather than one-off promotional activity.
Investors will also likely monitor execution risk around the product pipeline, particularly ahead of the hydration launch in late 2026 and the premium gummies line in 2027. Investors will want to see whether IM8 can maintain order cadence and international revenue mix as it adds new SKUs.
Finally, the financial guidance upgrades provide near-term benchmarks. Prenetics’ ability to sustain positive Adjusted Free Cash Flow while stepping up growth investments could shape sentiment going into subsequent quarterly updates.
Bigger picture
Prenetics said the Collins partnership supports its plan to build IM8 into a global consumer health and longevity brand. The company framed the collaboration as complementary to its broader strategy: international growth, a widening product pipeline, and improved cash flow.
In the current consumer health landscape, brand building and distribution expansion are central to scaling outcomes. A celebrity-led strategy can accelerate awareness, but the durability of demand typically depends on product performance and the company’s ability to keep expanding into new markets without eroding profitability.
Next, investors will likely watch how IM8’s international rollout and new-product planning progress, alongside quarterly reporting on revenue trajectory and cash flow. With Prenetics already guiding higher for fiscal 2026 and setting a 2027 target, upcoming disclosures on shipments, revenue mix outside the U.S., and progress toward maintaining positive Adjusted Free Cash Flow will be key.
